Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.
CompletedOBSERVATIONAL
Enrollment
55,589
Participants
Timeline
Start Date
October 10, 2023
Primary Completion Date
March 31, 2024
Study Completion Date
March 31, 2024
Conditions
Breast Cancer Female
Trial Locations (1)
69008
Hôpital Privé Jean Mermoz, Lyon
All Listed Sponsors
collaborator
Vivactis M2Research
INDUSTRY
lead
GCS Ramsay Santé pour l'Enseignement et la Recherche
OTHER
NCT06479772 - Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening. | Biotech Hunter | Biotech Hunter